US Dollar vs Yen

登録して無料でリアルタイムの株価、インタラクティブチャート、ライブオプションフローなどを入手してください。

登録

ホーム
投資
株式
アメリカ
NASDAQ
CRISPR Therapeutics AG (CRSP)
CRISPR Therapeutics AG (CRSP) ニュース

CRSP

CRISPR Therapeutics (CRSP)

CRISPR Therapeutics AG

から:

Regulatory News

Text Search:

次の項目別のソート:

Non-Regulatory News

Showing the most relevant articles for your search:NASDAQ:CRSP

1 2 3 4 5 6 7 8 9 10 次へ >>

日付	受信時刻	ニュースソース	見出し	コード	企業名
2024/05/09	21 : 30	GlobeNewswire Inc.	CRISPR Therapeutics to Present at the Bank of America Securities Health Care Conference	NASDAQ:CRSP	CRISPR Therapeutics AG
2024/05/09	05 : 20	Edgar (US Regulatory)	Form 10-Q - Quarterly report [Sections 13 or 15(d)]	NASDAQ:CRSP	CRISPR Therapeutics AG
2024/05/09	05 : 00	GlobeNewswire Inc.	CRISPR Therapeutics Provides Business Update and Reports First Quarter 2024 Financial Results	NASDAQ:CRSP	CRISPR Therapeutics AG
2024/05/08	20 : 00	GlobeNewswire Inc.	CRISPR Therapeutics Highlights ASGCT Oral Presentation and Announces New Programs Utilizing In Vivo Gene Editing Approach	NASDAQ:CRSP	CRISPR Therapeutics AG
2024/04/23	05 : 30	GlobeNewswire Inc.	CRISPR Therapeutics to Present Oral Presentation at the American Society of Gene & Cell Therapy (ASGCT) 2024 Annual Meeting	NASDAQ:CRSP	CRISPR Therapeutics AG
2024/04/03	21 : 00	GlobeNewswire Inc.	CRISPR Therapeutics to Present at the Annual Needham Virtual Healthcare Conference	NASDAQ:CRSP	CRISPR Therapeutics AG
2024/04/01	21 : 00	GlobeNewswire Inc.	CRISPR Therapeutics to Present at the American Society of Gene & Cell Therapy (ASGCT) 2024 Annual Meeting	NASDAQ:CRSP	CRISPR Therapeutics AG
2024/03/13	21 : 30	GlobeNewswire Inc.	CRISPR Therapeutics Proposes New Appointment to the Board of Directors	NASDAQ:CRSP	CRISPR Therapeutics AG
2024/02/22	07 : 45	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:CRSP	CRISPR Therapeutics AG
2024/02/22	07 : 45	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:CRSP	CRISPR Therapeutics AG
2024/02/21	21 : 50	Edgar (US Regulatory)	Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]	NASDAQ:CRSP	CRISPR Therapeutics AG
2024/02/21	21 : 45	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:CRSP	CRISPR Therapeutics AG
2024/02/21	21 : 30	GlobeNewswire Inc.	CRISPR Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results	NASDAQ:CRSP	CRISPR Therapeutics AG
2024/02/17	07 : 45	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:CRSP	CRISPR Therapeutics AG
2024/02/16	06 : 30	Edgar (US Regulatory)	Form 144 - Report of proposed sale of securities	NASDAQ:CRSP	CRISPR Therapeutics AG
2024/02/15	22 : 30	GlobeNewswire Inc.	CRISPR Therapeutics to Present at the Citi 2024 Virtual Oncology Leadership Summit	NASDAQ:CRSP	CRISPR Therapeutics AG
2024/02/13	22 : 44	Edgar (US Regulatory)	Form 424B5 - Prospectus [Rule 424(b)(5)]	NASDAQ:CRSP	CRISPR Therapeutics AG
2024/02/13	22 : 30	GlobeNewswire Inc.	CRISPR Therapeutics Announces $280 Million Registered Direct Offering	NASDAQ:CRSP	CRISPR Therapeutics AG
2024/02/13	20 : 30	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:CRSP	CRISPR Therapeutics AG
2024/02/13	16 : 30	GlobeNewswire Inc.	European Commission Approves First CRISPR/Cas9 Gene-Edited Therapy, CASGEVY™ (exagamglogene autotemcel), for the Treatment of Sickle Cell Disease (SCD) and Transfusion-Dependent Beta Thalassemia (TDT)	NASDAQ:CRSP	CRISPR Therapeutics AG
2024/02/01	07 : 45	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:CRSP	CRISPR Therapeutics AG
2024/01/30	06 : 08	Edgar (US Regulatory)	Form 144 - Report of proposed sale of securities	NASDAQ:CRSP	CRISPR Therapeutics AG
2024/01/30	06 : 00	Edgar (US Regulatory)	Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]	NASDAQ:CRSP	CRISPR Therapeutics AG
2024/01/19	07 : 45	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:CRSP	CRISPR Therapeutics AG
2024/01/17	07 : 00	Edgar (US Regulatory)	Form 144 - Report of proposed sale of securities	NASDAQ:CRSP	CRISPR Therapeutics AG
2024/01/17	06 : 11	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:CRSP	CRISPR Therapeutics AG
2024/01/17	06 : 01	GlobeNewswire Inc.	CRISPR Therapeutics Announces U.S. Food and Drug Administration (FDA) Approval of CASGEVY™ (exagamglogene autotemcel) for the Treatment of Transfusion-Dependent Beta Thalassemia	NASDAQ:CRSP	CRISPR Therapeutics AG
2024/01/11	01 : 36	Edgar (US Regulatory)	Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]	NASDAQ:CRSP	CRISPR Therapeutics AG
2024/01/08	21 : 00	GlobeNewswire Inc.	CRISPR Therapeutics Highlights Strategic Priorities and 2024 Outlook	NASDAQ:CRSP	CRISPR Therapeutics AG
2024/01/03	22 : 30	GlobeNewswire Inc.	CRISPR Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference	NASDAQ:CRSP	CRISPR Therapeutics AG

Showing the most relevant articles for your search:NASDAQ:CRSP

1 2 3 4 5 6 7 8 9 10 次へ >>

Allied Telesis Holdings KK (PK)

Seed Capital Solutions

Vanguard Australian Prop...

INTER CONSTRUTORA ON

FRCJ27 - 04/2027

Delayed Upgrade Clock

顧客サポート: +44 (0) 203 8794 460 | support@advfn.com

ADVFNのサービスをご利用いただくには、利用規約